In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
about
A Selection Fit Mechanism in BMP Receptor IA as a Possible Source for BMP Ligand-Receptor PromiscuityAffinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutProduction of recombinant antibodies using bacteriophages.Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversityHigh-affinity recombinant antibody fragments (Fabs) can be applied in peptide enrichment immuno-MRM assays.MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis.Directed evolution of human scFvs in DT40 cells.Site-saturation mutagenesis library construction and screening for specific broad-spectrum single-domain antibodies against multiple Cry1 toxins.Characterization of pathogenic human monoclonal autoantibodies against GM-CSF.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.Targeting GM-CSF in inflammatory diseases.Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway.Phage display-derived human antibodies in clinical development and therapyMolecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody.An automated immunoassay for early specificity profiling of antibodiesCrystallization of BMP receptor type IA bound to the antibody Fab fragment AbD1556.Driving chronicity in rheumatoid arthritis - perpetuating role of myeloid cells.Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
P2860
Q27664939-3AB0385E-887E-4CB6-A9FF-1B01205E23B2Q33495440-C7474459-E3CD-4528-A2BD-6785F9084545Q33643027-998DE0DF-00D9-49E0-ACB2-4E6BE1380693Q34244499-05069523-A095-4DC4-9109-555EE9A3C510Q34660961-90E945AC-CE4D-4E85-ABD3-42DD277B0380Q34672043-53F77CB4-1896-4057-8FF3-FA229895CF73Q35047704-18B9C83D-092F-445D-B903-975BB1CB7141Q35102677-1B52EB81-CB04-4648-A9B5-6E947DEA287FQ35605418-C471380E-03B0-4B66-8B07-007EE851052DQ35639941-97E01838-55FC-4D33-88FD-A87D1E7CC1AEQ35768564-F1AD0604-87AA-41A2-81FC-EAFD711239D1Q35828141-534B882F-FE83-4637-98CD-678D8AC5E673Q36397615-2CDE3671-88C1-403C-B54C-163B0207E2B5Q36835759-43F4D4BB-B72B-45EB-BDA1-7CC4331CC4B0Q37019872-84B35552-8895-453B-B661-6C2C96A32394Q37224687-87EDC2F6-B9DC-4905-B58B-6AE654DAACC2Q38235780-842B8B27-957D-4348-BB6A-16FBB9FFC65AQ38657999-F49F015A-0FA5-4891-8F8B-AEAC93F1DCEFQ38974299-344144F1-AC43-4954-AC4C-8D689804771AQ41416393-7414EC2B-426A-46A6-B017-B1D8F1999654Q41763168-1847F22E-44BE-4AE1-A34A-7679822707A7Q41874335-FF02247A-D6A3-4D9F-9041-3609DCB485BFQ42565831-44E6FB89-4B03-4899-AB86-BD62BE91AFF9Q47189951-02391830-1F8C-413F-880C-B9C9B4662CF9Q55309145-50738E37-6692-449A-88AA-4B38391A01C4
P2860
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@ast
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@en
type
label
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@ast
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@en
prefLabel
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@ast
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@en
P2093
P1433
P1476
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
@en
P2093
Bodo Brocks
Elisabeth Thomassen-Wolf
Manuela Dürr
Olaf Ratsch
Stefan Steidl
P304
P356
10.1016/J.MOLIMM.2008.07.013
P577
2008-08-21T00:00:00Z